Traumatic Brain Injury
Conditions
Brief summary
Traumatic brain injury (TBI) is the most common cause of death and disability in young adults. Patients can experience significant problems with concentration, attention, and memory (so called 'cognitive impairments') following TBI. These cognitive impairments can drastically impact on a patient's well-being, and can lead to significant economic and social consequences. Roughly a quarter of TBI patients improve but an equal number deteriorate over time. The investigators know little about why patients vary so much in how they recover. Crucially, the investigators have no treatments to improve brain functioning or recovery after TBI. Trials investigating ways of protecting the brain just after injury have been disappointing. An alternative strategy, however, is to improve the function of brain regions that remain intact, but that function inefficiently after TBI. The investigators know that dopamine (a chemical in the brain) is known to influence many brain functions and the investigators know that pathways in the brain that use dopamine are affected by TBI. In humans, drugs that increase dopamine in the brain, such as methylphenidate, are sometimes used to enhance cognitive function after TBI, but the response to treatment can be highly variable between patients. Therefore, what is needed in the clinic is a way to target the use of these drugs to patients who are likely to respond. In a single centre study, the investigators will use SPECT (Single Photon Emission Tomography) imaging to measure dopamine levels in the brain. MRI (Magnetic Resonance Imaging) scans will assess brain structure and function. The investigators will test whether treatment with methylphenidate improves cognitive functions in TBI patients who have ongoing cognitive problems, whether the mechanism involves a normalisation of brain functioning and whether brain dopamine levels can predict the magnitude of any improvement in symptoms.
Interventions
DRUGMethylphenidate
Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
DRUGPlacebo
Twice daily placebo tablet for two weeks
Sponsors
Imperial College London
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* a diagnosis of a moderate-severe traumatic brain injury (as defined by the Mayo TBI severity classification system) at least 3 months prior to recruitment into the study * age between 20 and 65 years * capable of giving written informed consent subjective complaint of cognitive difficulties by the participant, treating clinician, or caregiver
Exclusion criteria
* unwillingness or inability to follow the procedures required * significant neurological or psychiatric illness diagnosed prior to the TBI * family history of a first degree relative with a psychotic illness * currently participating in a clinical trial or has done so within 1 month before screening * use of any medication or substance that, in the opinion of the investigators, would interfere with the study or compromise participant safety * history of a drug or other allergy that, in the opinion of the investigators, contraindicates their participation in the study * history of current or past drug or alcohol addiction * female participants who are breast feeding or pregnant (positive pregnancy test) or plan to become pregnant during the study * positive urine drug screen * contraindication to MRI scanning, assessed by a standard pre-MRI questionnaire * contraindication to the use of methylphenidate (including medications deemed to have a potentially serious interaction with methylphenidate as per the British National Formulary) * clinical evidence of motor symptoms of Parkinsonism as assessed by a Neurologist
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in Choice Reaction Time task with methylphenidate treatment in patients and its relationship to specific binding ratio (SBR) of the dopamine transporter (DAT) in the striatum. | On completion of the four week drug trial phase |
Countries
United Kingdom
Outcome results
None listed